1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-05 am EDT
316.70 CHF   -0.02%
08/07Amgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/03Roche Signs Partnership Deal with Poseida On Hematologic Therapies
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Switzerland's Roche Introduces New Tissue Staining Platform For Cancer Diagnostics

06/29/2022 | 01:29am EDT


© MT Newswires 2022
All news about ROCHE HOLDING AG
08/07Amgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/03Roche Signs Partnership Deal with Poseida On Hematologic Therapies
MT
08/03Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on All..
CI
08/03Poseida Therapeutics Inks Collaboration With Roche
DJ
08/03Kiniksa Pharmaceuticals in Global License Deal With Genentech for Vixarelimab
DJ
08/03Coherus BioSciences Shares Rise Premarket on FDA Approval of Lucentis Biosimilar
DJ
08/02Roche's New Lung Cancer Therapy Formula Shows Efficacy In Late-stage Trial
MT
08/02Halozyme Therapeutics Says Phase 3 Study Evaluating Formulation of Tecentriq with Enhan..
MT
08/02Genentech's Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Resul..
BU
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 190 M 66 541 M 66 541 M
Net income 2022 14 826 M 15 369 M 15 369 M
Net Debt 2022 10 272 M 10 648 M 10 648 M
P/E ratio 2022 17,0x
Yield 2022 3,05%
Capitalization 262 B 271 B 271 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,11x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 316,70 CHF
Average target price 374,13 CHF
Spread / Average Target 18,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.46%271 358
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ABBVIE INC.1.95%244 068
NOVO NORDISK A/S2.86%233 797